Risk Reduction Strategies in Ischaemic Stroke: The Role of Antiplatelet Therapy

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.24, Iss.5, 2004-01, pp. : 245-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiplatelet therapy in secondary stroke prevention

By Crawford K Michelle Talbert Robert L

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 10, 2001-10 ,pp. : 1609-1613

Informa Healthcare

Access to resources Recommend Favorite

Stroke: antithrombin versus antiplatelet therapy

By Bednar M.M.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 2, 2000-02 ,pp. : 355-369

Informa Healthcare

Access to resources Recommend Favorite

Anticoagulants offer no net advantages over antiplatelet agents in acute ischaemic stroke

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke

Current Pharmaceutical Design, Vol. 18, Iss. 33, 2012-11 ,pp. : 5261-5272

Bentham Science Publishers

Access to resources Recommend Favorite

Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke

By Madden K.

CNS Drugs, Vol. 16, Iss. 4, 2002-01 ,pp. : 213-218

Adis International

Access to resources Recommend Favorite